NASDAQ:CLDX - Celldex Therapeutics Stock Price, Price Target & More

$0.71 +0.02 (+2.90 %)

(As of 04/25/2018 02:42 AM ET)

Previous Close$0.69

Today's Range$0.67 - $0.72

52-Week Range$0.65 - $3.41

Volume3.79 million shs

Average Volume2.23 million shs

Market Capitalization$98.77 million

P/E Ratio-0.89

Dividend YieldN/A

Beta2.44

About Celldex Therapeutics (NASDAQ:CLDX)

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of various immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer; and CDX-3379, a human monoclonal antibody that is in Phase II study in combination with cetuximab for the treatment of head and neck squamous cell carcinoma. The company also develops earlier stage drug candidates that are in clinical development, including CDX-014, an antibody-drug conjugate targeting renal and ovarian cancers; CDX-1140, a human monoclonal antibody; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-1401, an immunotherapeutic aimed at antigen presenting cells for cancer indications. Celldex Therapeutics, Inc. has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; University of Southampton; Amgen Inc.; Amgen Fremont; Seattle Genetics, Inc.; Yale University; and MedImmune, LLC. The company is headquartered in Hampton, New Jersey.

Receive CLDX News and Ratings via Email

Sign-up to receive the latest news and ratings for CLDX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Diagnostic substances

Sub-IndustryBiotechnology

SectorMedical

SymbolNASDAQ:CLDX

CUSIP15117B10

Webwww.celldextherapeutics.com

Phone908-200-7500

Debt

Debt-to-Equity RatioN/A

Current Ratio5.22%

Quick Ratio5.22%

Price-To-Earnings

Trailing P/E Ratio-0.89

Forward P/E Ratio-0.95

P/E GrowthN/A

Sales & Book Value

Annual Sales$12.74 million

Price / Sales7.86

Cash FlowN/A

Price / CashN/A

Book Value$1.74 per share

Price / Book0.41

Profitability

EPS (Most Recent Fiscal Year)($0.80)

Net Income$-93,030,000.00

Net Margins-730.06%

Return on Equity-44.64%

Return on Assets-31.11%

Miscellaneous

Employees197

Outstanding Shares141,070,000

How to Become a New Pot Stock Millionaire

Celldex Therapeutics (NASDAQ:CLDX) Frequently Asked Questions

What is Celldex Therapeutics' stock symbol?

Celldex Therapeutics trades on the NASDAQ under the ticker symbol "CLDX."

How were Celldex Therapeutics' earnings last quarter?

Celldex Therapeutics, Inc. (NASDAQ:CLDX) issued its earnings results on Wednesday, March, 7th. The biopharmaceutical company reported ($0.17) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.08. The biopharmaceutical company earned $3.50 million during the quarter, compared to the consensus estimate of $1.49 million. Celldex Therapeutics had a negative net margin of 730.06% and a negative return on equity of 44.64%. The company's revenue was up 87.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.30) earnings per share. View Celldex Therapeutics' Earnings History.

When is Celldex Therapeutics' next earnings date?

Celldex Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, May, 7th 2018. View Earnings Estimates for Celldex Therapeutics.

What price target have analysts set for CLDX?

7 equities research analysts have issued 1-year price objectives for Celldex Therapeutics' stock. Their forecasts range from $3.00 to $10.00. On average, they anticipate Celldex Therapeutics' share price to reach $4.50 in the next year. View Analyst Ratings for Celldex Therapeutics.

What are Wall Street analysts saying about Celldex Therapeutics stock?

Here are some recent quotes from research analysts about Celldex Therapeutics stock:

1. Cantor Fitzgerald analysts commented, "Glemba is a Miss. The METRIC trial evaluating metastatic TNBC patients that overexpress gpNMB versus capecitibine did not achieve statistical significance, with glemba-treated patients experiencing PFS of 2.7 months versus 2.6 months for capecitibine, p=0.76. Additionally, significance was not achieved for key secondary endpoints of OR (overall response), DoR (Duration of Response) or OS (Overall Survival)." (4/17/2018)
2. According to Zacks Investment Research, "Celldex’s efforts to build its immuno-oncology pipeline are impressive. Its lead pipeline candidate, glembatumumab vedotin, is in mid-stage development for different types of cancer. Apart from glembatumumab vedotin, Celldex has several promising candidates in its pipeline, including varlilumab. We are also encouraged by Celldex’s partnership agreements with big players like Bristol-Myers. Meanwhile, the recent Kolltan acquisition adds some interesting candidates to the company’s pipeline. However, with no approved product in its portfolio, Celldex has to depend entirely on product development and licensing agreements, contracts and grants for revenues. We are also concerned about the early- to mid-stage nature of its pipeline. Estimates have remained mostly stable lately ahead of the Q2 results. Celldex has a positive record of earnings surprises in the recent quarters. " (7/17/2017)
3. Cowen Inc analysts commented, "At ASCO updates on varli and glemba were provided." (6/6/2017)

Are investors shorting Celldex Therapeutics?

Celldex Therapeutics saw a increase in short interest in the month of April. As of April 13th, there was short interest totalling 10,445,637 shares, an increase of 14.7% from the March 30th total of 9,103,227 shares. Based on an average trading volume of 1,438,107 shares, the days-to-cover ratio is currently 7.3 days. Approximately 7.4% of the company's shares are short sold.

Who are some of Celldex Therapeutics' key competitors?

Some companies that are related to Celldex Therapeutics include Oxford Immunotec Global (OXFD), Nymox Pharmaceutical (NYMX), Quotient (QTNT), Trinity Biotech (TRIB), AspenBio Pharma (RIOT), Vermillion (VRML), Akers Biosciences (AKER), ImmuCell (ICCC), Achieve Life Sciences (ACHV), Genenews (GNWSF), ARCA biopharma (ABIO), FluoroPharma Medical (FPMI), BG Medicine (BGMD), Response Genetics (RGDXQ) and Palatin Technologies (PTN).

Who are Celldex Therapeutics' key executives?

Celldex Therapeutics' management team includes the folowing people:

Mr. Anthony S. Marucci, Founder, Pres, CEO & Director (Age 56)
Dr. Tibor Keler Ph.D., Founder, Chief Scientific Officer and Exec. VP (Age 59)
Ms. Elizabeth Crowley, Chief Product Devel. Officer and Sr. VP (Age 46)
Mr. Sam Martin, Sr. VP, CFO, Principal Accounting Officer & Treasurer
Ms. Sarah Cavanaugh, Sr. VP of Corp. Affairs & Admin.

Has Celldex Therapeutics been receiving favorable news coverage?

News headlines about CLDX stock have been trending somewhat positive on Wednesday, according to Accern Sentiment. Accern ranks the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Celldex Therapeutics earned a media sentiment score of 0.20 on Accern's scale. They also gave news coverage about the biopharmaceutical company an impact score of 44.92 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future.

How do I buy shares of Celldex Therapeutics?

Shares of CLDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Celldex Therapeutics' stock price today?

One share of CLDX stock can currently be purchased for approximately $0.71.

How big of a company is Celldex Therapeutics?

Celldex Therapeutics has a market capitalization of $98.77 million and generates $12.74 million in revenue each year. The biopharmaceutical company earns $-93,030,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis. Celldex Therapeutics employs 197 workers across the globe.

How can I contact Celldex Therapeutics?

Celldex Therapeutics' mailing address is 53 FRONTAGE ROAD SUITE 220, HAMPTON NJ, 08827. The biopharmaceutical company can be reached via phone at 908-200-7500 or via email at [email protected]

MarketBeat Community Rating for Celldex Therapeutics (CLDX)

Community Ranking:		3.3 out of 5 ( )
Outperform Votes:		389 (Vote Outperform)
Underperform Votes:		198 (Vote Underperform)
Total Votes:		587

MarketBeat's community ratings are surveys of what our community members think about Celldex Therapeutics and other stocks. Vote "Outperform" if you believe CLDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLDX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Celldex Therapeutics (NASDAQ:CLDX) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

7 Wall Street analysts have issued ratings and price targets for Celldex Therapeutics in the last 12 months. Their average twelve-month price target is $4.50, suggesting that the stock has a possible upside of 533.80%. The high price target for CLDX is $10.00 and the low price target for CLDX is $3.00. There are currently 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus rating of "Hold."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Hold	Buy	Buy	Buy
Consensus Rating Score:	2.43	2.71	2.83	2.71
Ratings Breakdown:	0 Sell Rating(s) 4 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 5 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 5 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 5 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$4.50	$7.10	$8.1250	$6.50
Price Target Upside:	533.80% upside	168.94% upside	180.17% upside	131.32% upside

Celldex Therapeutics (NASDAQ:CLDX) Consensus Price Target History

Price Target History for Celldex Therapeutics (NASDAQ:CLDX)

Celldex Therapeutics (NASDAQ:CLDX) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/17/2018	Cantor Fitzgerald	Downgrade	Overweight -> Neutral	$3.00	Low
4/16/2018	Cowen	Downgrade	Outperform -> Market Perform		High
4/16/2018	HC Wainwright	Set Price Target	Buy	$3.00	High
3/8/2018	Leerink Swann	Reiterated Rating	Market Perform -> Market Perform	$4.00 -> $3.00	High
12/6/2017	WBB Securities	Reiterated Rating	Buy	$10.00	Low
6/29/2017	Aegis	Reiterated Rating	Buy		Medium
5/11/2017	Jefferies Group	Reiterated Rating	Hold	$4.00 -> $3.50	High
11/10/2016	Roth Capital	Reiterated Rating	Buy	$7.00	N/A
11/8/2016	Wedbush	Reiterated Rating	Neutral	$3.00	N/A
10/4/2016	Brean Capital	Initiated Coverage	Buy	$16.00	N/A

(Data available from 4/25/2016 forward)

Celldex Therapeutics (NASDAQ:CLDX) Earnings History and Estimates Chart

Earnings by Quarter for Celldex Therapeutics (NASDAQ:CLDX)

Celldex Therapeutics (NASDAQ:CLDX) Earnings Estimates

2018 EPS Consensus Estimate: ($0.96)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	2	($0.20)	($0.19)	($0.20)
Q2 2018	2	($0.21)	($0.20)	($0.21)
Q3 2018	2	($0.27)	($0.22)	($0.25)
Q4 2018	2	($0.39)	($0.24)	($0.32)

Celldex Therapeutics (NASDAQ CLDX) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/7/2018		($0.22)					N/A
3/7/2018	Q4 2017	($0.25)	($0.17)	$1.49 million	$3.50 million	View	Listen
11/7/2017	Q3 2017	($0.27)	($0.20)	$1.30 million	$3.90 million	View	N/A
8/8/2017	Q2 2017	($0.28)	($0.23)	$1.21 million	$3.83 million	View	Listen
5/9/2017	Q1 2017	($0.2850)	($0.28)	$0.57 million	$1.53 million	View	N/A
3/14/2017	Q4 2016	($0.34)	($0.30)	$1.10 million	$1.87 million	View	Listen
11/7/2016	Q3 2016	($0.33)	($0.29)	$1.09 million	$2.20 million	View	N/A
8/8/2016	Q2	($0.34)	($0.32)	$0.96 million	$1.39 million	View	Listen
5/5/2016	Q1 16	($0.35)	($0.35)	$1.06 million	$1.30 million	View	N/A
2/25/2016	Q415	($0.35)	($0.33)	$0.80 million	$1.80 million	View	Listen
11/5/2015	Q3	($0.35)	($0.32)	$1.02 million	$1.03 million	View	N/A
8/10/2015	Q215	($0.34)	($0.33)	$0.51 million	$2.18 million	View	Listen
4/29/2015	Q115	($0.36)	($0.33)	$0.52 million	$0.49 million	View	N/A
2/24/2015	Q314	($0.35)	($0.36)	$0.49 million	$1.50 million	View	N/A
11/4/2014	Q3	($0.33)	($0.31)	$0.43 million	$1.10 million	View	N/A
8/6/2014	Q214	($0.31)	($0.32)	$0.38 million	$0.60 million	View	N/A
5/1/2014	Q1 2014	($0.26)	($0.33)	$0.34 million	$0.40 million	View	N/A
3/3/2014	Q413	($0.28)	($0.27)	$0.27 million	$0.62 million	View	N/A
11/5/2013	Q313	($0.24)	($0.29)	$0.09 million	$1.00 million	View	N/A
8/6/2013	Q2 2013	($0.22)	($0.24)	$1.57 million	$0.97 million	View	N/A
5/2/2013	Q1 2013	($0.22)	($0.23)	$2.65 million	$2.41 million	View	N/A
3/7/2013	Q4 2012	($0.25)	($0.27)	$2.45 million	$3.65 million	View	N/A
11/1/2012	Q312	($0.24)	($0.25)	$2.07 million	$3.11 million	View	N/A
8/10/2012		($0.25)	($0.23)			View	N/A
5/3/2012		($0.25)	($0.27)			View	N/A
3/7/2012		($0.26)	($0.29)			View	N/A
11/2/2011	Q3 2011	($0.26)	($0.27)			View	N/A
8/3/2011	Q2 2011	($0.28)	($0.27)			View	N/A
5/4/2011	Q1 2011	($0.30)	($0.30)			View	N/A
3/3/2011	Q4 2010	$0.21	($0.24)			View	N/A
11/2/2010	Q3 2010	($0.33)	($0.29)			View	N/A
8/4/2010	Q2 2010	($0.26)	($0.30)			View	N/A
5/4/2010	Q1 2010	($0.26)	($0.16)			View	N/A
3/4/2010	Q4 2009	($0.29)	($0.27)			View	N/A
11/4/2009	Q3 2009	($0.56)	($0.45)			View	N/A
8/5/2009	Q2 2009	($0.47)	($0.55)			View	N/A
5/5/2009	Q1 2009	($0.46)	($0.49)			View	N/A
2/27/2009	Q4 2008	($0.54)	($0.47)			View	N/A
11/5/2008	Q3 2008	($0.41)	($0.50)			View	N/A
8/6/2008	Q2 2008	($0.56)	($0.67)			View	N/A
5/19/2008	Q1 2008	($0.67)	($0.73)			View	N/A
2/27/2008	Q4 2007		($0.84)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Celldex Therapeutics (NASDAQ:CLDX) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Celldex Therapeutics (NASDAQ CLDX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.10%
Institutional Ownership Percentage: 55.66%

Insider Trading History for Celldex Therapeutics (NASDAQ:CLDX)

Institutional Ownership by Quarter for Celldex Therapeutics (NASDAQ:CLDX)

Celldex Therapeutics (NASDAQ CLDX) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/2/2016	Tibor Keler	VP	Buy	3,000	$3.32	$9,960.00	18,868
11/23/2015	Avery W. Catlin	CFO	Sell	25,000	$18.00	$450,000.00	35,109
8/25/2015	Larry Ellberger	Director	Buy	5,000	$14.00	$70,000.00	53,500
8/20/2015	Larry Ellberger	Director	Buy	5,000	$15.00	$75,000.00	48,500
8/18/2015	Larry Ellberger	Director	Buy	5,000	$15.95	$79,750.00	43,500
8/13/2015	Anthony S Marucci	CEO	Buy	5,800	$16.81	$97,498.00
8/13/2015	Larry Ellberger	Director	Buy	5,000	$16.59	$82,950.00
6/15/2015	Avery W Catlin	CFO	Sell	25,000	$24.59	$614,750.00
12/6/2013	Avery Catlin	CFO	Sell	183,333	$24.50	$4,491,658.50	14,109
12/6/2013	Larry Ellberger	Director	Sell	17,728	$24.50	$434,336.00	25,000

(Data available from 1/1/2013 forward)

Celldex Therapeutics (NASDAQ CLDX) News Headlines

Source:

Date	Headline
	BRIEF-Celldex Therapeutics Approves Workforce Reduction www.reuters.com - April 24 at 5:16 PM
	Brokerages Anticipate Celldex Therapeutics, Inc. (CLDX) Will Post Quarterly Sales of $2.03 Million www.americanbankingnews.com - April 24 at 3:04 AM
	Is It Game Over for Celldex? finance.yahoo.com - April 23 at 4:56 PM
	Cantor Fitzgerald Brokers Reduce Earnings Estimates for Celldex Therapeutics, Inc. (CLDX) www.americanbankingnews.com - April 23 at 2:48 AM
	Celldex Therapeutics, Inc. (CLDX) Expected to Post Earnings of -$0.17 Per Share www.americanbankingnews.com - April 22 at 11:15 AM
	Celldex (CLDX) Says Data from Multiple Programs Presented at AACR www.streetinsider.com - April 21 at 5:00 PM
	Data from Multiple Celldex Programs Presented at American Association for Cancer Research (AACR) Annual Meeting ... globenewswire.com - April 20 at 5:03 PM
	3 Things In Biotech, April 18: Bristol Plows Ahead, Celldex Flops, Alkermes Gets A Surprise seekingalpha.com - April 19 at 8:42 AM
	Jefferies Group Weighs in on Celldex Therapeutics, Inc.'s FY2021 Earnings (CLDX) www.americanbankingnews.com - April 19 at 7:38 AM
	Celldex Tumbles On Phase 2 Trial Failure; Is There Any Value Left? seekingalpha.com - April 18 at 5:22 PM
	Celldex's Phase II Breast Cancer Study Fails, Shares Plunge finance.yahoo.com - April 17 at 5:33 PM
	Celldex's Phase II Breast Cancer Study Fails, Shares Plunge finance.yahoo.com - April 17 at 5:33 PM
	Celldex Therapeutics (CLDX) Stock Rating Lowered by Cantor Fitzgerald www.americanbankingnews.com - April 17 at 11:04 AM
	Celldex Therapeutics (CLDX) Rating Lowered to Strong Sell at BidaskClub www.americanbankingnews.com - April 16 at 8:40 PM
	CLDX Apr 2018 5.000 put finance.yahoo.com - April 16 at 5:02 PM
	Why Celldex Therapeutics Is Getting Crushed 247wallst.com - April 16 at 5:02 PM
	Why Celldex Therapeutics Stock Is Cratering Today finance.yahoo.com - April 16 at 5:02 PM
	Cowen Downgrades Celldex Therapeutics (CLDX) to Market Perform www.americanbankingnews.com - April 16 at 1:21 PM
	Celldex Therapeutics (CLDX) Downgraded by HC Wainwright to Buy www.americanbankingnews.com - April 16 at 12:05 PM
	Celldex's lead candidate flunks breast cancer study; shares down 51% premarket seekingalpha.com - April 16 at 8:39 AM
	Celldex To Discontinue Glembatumumab Vedotin Program Across All Indications www.nasdaq.com - April 16 at 8:39 AM
	Celldex's stock plummets toward record low after failed drug study finance.yahoo.com - April 16 at 8:39 AM
	Celldex’s METRIC Study in Metastatic Triple-negative Breast Cancer Does Not Meet Primary Endpoint finance.yahoo.com - April 16 at 8:39 AM
	Celldex Therapeutics (CLDX) Earns "Buy" Rating from HC Wainwright www.americanbankingnews.com - April 14 at 3:38 PM
	Celldex Therapeutics (CLDX) Upgraded to "Hold" by BidaskClub www.americanbankingnews.com - April 14 at 7:21 AM
	HC Wainwright Analysts Give Celldex Therapeutics (CLDX) a $10.00 Price Target www.americanbankingnews.com - April 11 at 11:52 PM
	Implied Volatility Surging for Celldex Therapeutics (CLDX) Stock Options www.zacks.com - April 10 at 9:01 AM
	$2.03 Million in Sales Expected for Celldex Therapeutics, Inc. (CLDX) This Quarter www.americanbankingnews.com - April 7 at 3:07 AM
	Financial Survey: Oxford Immunotec Global (OXFD) & Celldex Therapeutics (CLDX) www.americanbankingnews.com - April 6 at 1:23 AM
	Celldex Therapeutics (CLDX) Cut to "Sell" at BidaskClub www.americanbankingnews.com - April 5 at 10:33 AM
	Celldex Therapeutics Inc (NASDAQ:CLDX): Has Recent Earnings Growth Beaten Long-Term Trend? finance.yahoo.com - April 4 at 8:47 AM
	Celldex Therapeutics, Inc. (CLDX) Given Average Rating of "Hold" by Analysts www.americanbankingnews.com - April 1 at 3:32 PM
	Celldex Therapeutics (CLDX) Receives Buy Rating from HC Wainwright www.americanbankingnews.com - March 31 at 8:52 PM
	Celldex Therapeutics Inc (NASDAQ:CLDX): Are Analysts Optimistic? finance.yahoo.com - March 27 at 9:00 AM
	Analysts Expect Celldex Therapeutics, Inc. (CLDX) Will Announce Quarterly Sales of $2.42 Million www.americanbankingnews.com - March 21 at 4:10 AM
	What Do Analysts Think About Celldex Therapeutics Inc’s (NASDAQ:CLDX) Future? finance.yahoo.com - March 16 at 6:05 PM
	Why Celldex Therapeutics Stock Crashed in February -- The Motley ... - Motley Fool www.fool.com - March 14 at 6:35 PM
	Is Celldex Therapeutics Stock About to Skyrocket? finance.yahoo.com - March 13 at 8:55 AM
	Why Celldex Therapeutics Stock Crashed in February finance.yahoo.com - March 13 at 8:55 AM
	Leerink Swann Equities Analysts Decrease Earnings Estimates for Celldex Therapeutics, Inc. (CLDX) www.americanbankingnews.com - March 12 at 6:06 AM
	Brokers Offer Predictions for Celldex Therapeutics, Inc.'s Q1 2018 Earnings (CLDX) www.americanbankingnews.com - March 12 at 2:32 AM
	Jefferies Group Weighs in on Celldex Therapeutics, Inc.'s FY2022 Earnings (CLDX) www.americanbankingnews.com - March 9 at 4:33 PM
	Celldex Therapeutics: Make-or-Break-It Data Expected Soon finance.yahoo.com - March 9 at 8:56 AM
	Celldex Therapeutics, Inc. Forecasted to Post Q1 2018 Earnings of ($0.19) Per Share (CLDX) www.americanbankingnews.com - March 9 at 8:04 AM
	Leerink Swann Cuts Celldex Therapeutics (CLDX) Price Target to $3.00 www.americanbankingnews.com - March 8 at 8:19 PM
	Why Celldex Therapeutics Shot Up Today finance.yahoo.com - March 8 at 6:10 PM
	Celldex (CLDX) Q4 Loss Narrows, Revenues Beat, Shares Up finance.yahoo.com - March 8 at 6:10 PM
	Celldex Therapeutics Finishes 2017 With Plenty of Cash and High Hopes finance.yahoo.com - March 8 at 6:10 PM
	Celldex Therapeutics (CLDX) Posts Quarterly Earnings Results, Beats Estimates By $0.08 EPS www.americanbankingnews.com - March 8 at 10:56 AM
	Today’s Research Reports on Trending Tickers: Celldex Therapeutics, Inc. and Geron Corporation finance.yahoo.com - March 8 at 8:52 AM

Celldex Therapeutics (NASDAQ:CLDX) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Celldex Therapeutics (NASDAQ:CLDX) Income Statement, Balance Sheet and Cash Flow Statement

Celldex Therapeutics (NASDAQ CLDX) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff